Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
ACC 2009 Survey Results and Recommendations: Addressing the Cardiology Workforce Crisis
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:1675-1684, doi:10.1016/j.jacc.2008.01.028
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow View Cardiosource Slide Set
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yancy, C. W.
Right arrow Articles by Fonarow, G. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Yancy, C. W.
Right arrow Articles by Fonarow, G. C.

Quality of Care of and Outcomes for African Americans Hospitalized With Heart Failure

Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry

Clyde W. Yancy, MD, FACC*,*, William T. Abraham, MD, FACC{dagger}, Nancy M. Albert, PhD, RN{ddagger}, Robert Clare, MS§, Wendy Gattis Stough, PharmD||,¶, Mihai Gheorghiade, MD, FACC#, Barry H. Greenberg, MD, FACC**, Christopher M. O'Connor, MD, FACC{dagger}{dagger}, Lilin She, PhD§, Jie Lena Sun, MS§, James B. Young, MD, FACC{ddagger}{ddagger} and Gregg C. Fonarow, MD, FACC§§

* Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas
{dagger} Division of Cardiology, Ohio State University, Columbus, Ohio
{ddagger} George M. and Linda H. Kaufman Center for Heart Failure, Durham, North Carolina
§ Duke Clinical Research Institute, Durham, North Carolina
|| Department of Clinical Research, Campbell University School of Pharmacy, Research Triangle Park, North Carolina
Department of Medicine, Duke University Medical Center, Durham, North Carolina
# Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
** Department of Medicine, University of California San Diego Medical Center, San Diego, California
{dagger}{dagger} Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina
{ddagger}{ddagger} Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
§§ Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California.


Figure 1
View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Heart Failure Measures at Hospital Discharge

Percent of patients who received heart failure measures at hospital discharge by race. ACE = angiotensin-converting enzyme; LVEF = left ventricular ejection fraction.

 

Figure 2
View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Other Medications at Hospital Discharge

Eligible patients receiving other medications at hospital discharge by race. *ACE inhibitor and/or ARB use in patients with left ventricular systolic dysfunction (LVSD), excluding patients with contraindications to ACE inhibitor and/or ARB. {dagger}Beta-blocker use in patients with LVSD, excluding patients with contraindications to beta-blocker drugs. {ddagger}Statin use in patients with medical history of coronary artery disease, cerebral vascular accident/transient ischemic attack, diabetes, hyperlipidemia, or peripheral vascular disease. §Aldosterone antagonist, hydralazine, and nitrate use in patients with LVSD. ||Warfarin use in patients with chronic or paroxysmal atrial fibrillation. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; HYDR/ISDN = hydralazine/isosorbide dinitrate.

 

Figure 3
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Outcomes in Patients With Left Ventricular Systolic Dysfunction

(A) In-hospital outcomes in heart failure patients with left ventricular systolic dysfunction (LVSD) by race. (B) The 60- to 90-day post-discharge outcomes in heart failure patients with LVSD by race.

 

Figure 4
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 Outcomes in Patients Without LVSD

(A) In-hospital outcomes in heart failure patients without left ventricular systolic dysfunction (LVSD) by race. (B) The 60- to 90-day post-discharge outcomes in heart failure patients without LVSD by race.

 
 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement